Here we present findings from a phase II study of AGSC3F versus axitinib in metastatic renal cell carcinoma (mRCC). Patients with mRCC of any histology and disease progression during or after their last treatment regimen were randomized 1:1 to intravenous AGSC3F 1.8 mg/kg every 3 weeks or ...